Cancers Journal Publication: Discovery of VIP236, an avb3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors

VINC 10.30.2024

Full Press ReleaseSEC FilingsOur VINC Tweets

About Gravity Analytica

Recent News

  • 12.27.2024 - Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
  • 12.04.2024 - Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
  • 11.12.2024 - Vincerx Pharma Reports Third Quarter 2024 Financial Results

Recent Filings

  • 01.21.2025 - 424B5 Prospectus [Rule 424(b)(5)]
  • 01.21.2025 - 8-K Current report
  • 01.21.2025 - EX-99.1 EX-99.1
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com